Alnylam Pharmaceuticals, Inc.

US$155.94As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ALNYHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 15.88%
Div yield —
ROE 138.07%
Biotechnology
Beta (5Y) 0.44
PE TTM 8.085
TSR TTM (65.81%)
Mkt cap US$20.89B
ROIC 48.31%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$174
11.33%
(71.81%)
Hold 3|10|4|9|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
3.36
3.60
3.79
4.18
17.83%
19.95%
25.98%
30.71%
Revenue$M
896.9
943.7
938.1
914.6
1.89%
4.97%
5.45%
1.15%
Peers (US$20.89B)
Cap (US$)
PE
24.39B
61.55x
16.98B
20.78x
21.70B
—
Capital
TTM
5Y
10Y
Leveragex
1.015
2.252
1.728
EBIT/Intx
0.936
0.192
0.185
Own earn%
(92.86)
45.78
46.62
Sh yield%
14.75
31.91
30.24
Owners
Insiders/Inst%
11.49
70.67
Short interest%
3.10
SBC / revenue%
3.02
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
20–31
$1 testx
0.0
Incr. ROIC%
9